Human engineered heart tissue models for disease modeling and drug discovery

H Tani, S Tohyama - Frontiers in Cell and Developmental Biology, 2022 - frontiersin.org
The emergence of human induced pluripotent stem cells (hiPSCs) and efficient
differentiation of hiPSC-derived cardiomyocytes (hiPSC-CMs) induced from diseased …

Generating 3D human cardiac constructs from pluripotent stem cells

C Liu, X Feng, G Li, P Gokulnath, J Xiao - EBioMedicine, 2022 - thelancet.com
Human pluripotent stem cell (hPSC) technology has offered nearly infinite opportunities to
model all kinds of human diseases in vitro. Cardiomyocytes derived from hPSCs have …

[HTML][HTML] A deep learning platform to assess drug proarrhythmia risk

R Serrano, DAM Feyen, AAN Bruyneel, AP Hnatiuk… - Cell Stem Cell, 2023 - cell.com
Drug safety initiatives have endorsed human iPSC-derived cardiomyocytes (hiPSC-CMs) as
an in vitro model for predicting drug-induced cardiac arrhythmia. However, the extent to …

Ion Channel Impairment and Myofilament Ca2+ Sensitization: Two Parallel Mechanisms Underlying Arrhythmogenesis in Hypertrophic Cardiomyopathy

L Santini, R Coppini, E Cerbai - Cells, 2021 - mdpi.com
Life-threatening ventricular arrhythmias are the main clinical burden in patients with
hypertrophic cardiomyopathy (HCM), and frequently occur in young patients with mild …

Human induced pluripotent stem cell-derived cardiomyocytes as an electrophysiological model: Opportunities and challenges—The Hamburg perspective

D Ismaili, C Schulz, A Horváth, JT Koivumäki… - Frontiers in …, 2023 - frontiersin.org
Models based on human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM)
are proposed in almost any field of physiology and pharmacology. The development of …

Advances in Hypertrophic Cardiomyopathy Disease Modelling Using hiPSC-Derived Cardiomyocytes

S Dababneh, H Hamledari, Y Maaref, F Jayousi… - Canadian Journal of …, 2024 - Elsevier
The advent of human induced pluripotent stem cells (hiPSCs) and their capacity to be
differentiated into beating human cardiomyocytes (CMs) in vitro has revolutionized human …

[HTML][HTML] Human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte modelling of cardiovascular diseases for natural compound discovery

K Zhu, X Bao, Y Wang, T Lu, L Zhang - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Cardiovascular disease (CVD) remains the leading cause of death worldwide. Natural
compounds extracted from medicinal plants characterized by diverse biological activities …

Ventricular arrhythmia and sudden cardiac death in hypertrophic cardiomyopathy: From bench to bedside

H Shen, SY Dong, MS Ren, R Wang - Frontiers in cardiovascular …, 2022 - frontiersin.org
Patients with hypertrophic cardiomyopathy (HCM) mostly experience minimal symptoms
throughout their lifetime, and some individuals have an increased risk of ventricular …

ISE/ISHNE expert consensus statement on ECG diagnosis of left ventricular hypertrophy: the change of the paradigm. The joint paper of the International Society of …

L Bacharova, P Chevalier, B Gorenek, C Jons… - Journal of …, 2023 - Elsevier
The ECG diagnosis of LVH is predominantly based on the QRS voltage criteria, ie the
increased QRS complex amplitude in defined leads. The classical ECG diagnostic paradigm …

Modulation of cardiac voltage-activated K+ currents by glypican 1 heparan sulfate proteoglycan

DS Souza, AZ Chignalia, JL Carvalho-de-Souza - Life sciences, 2022 - Elsevier
Abstract Background Glypican 1 (Gpc1) is a heparan sulfate proteoglycan attached to the
cell membrane via a glycosylphosphatidylinositol anchor, where it holds …